

# References

1. Abauf, N., and Carmody, K., "The Cost of Capital in Japan and the United States: A Tale of Two Markets," Salomon Brothers Financial Strategy Group, July 1990.
2. Abe, M., Deputy Director, Economic Affairs Division, Pharmaceutical Advisory Board, Ministry of Health and Welfare of Japan, unpublished minutes from Board of Directors meeting, Siegel Associates, New York, NY, June 20, 1991.
3. Adler, R. G., Director, Office of Technology Transfer, National Institutes of Health, Public Health Service, U.S. Department of Health and Human Services, personal communications, February 8, 1990, February 21, 1990, February 26, 1990, April 12, 1991, and September 18, 1992.
4. Alderman, M. H., "Which Antihypertensive Drugs First-and Why!" [commentary] *Journal of the American Medical Association* 267(20):2786-2787, 1992.
5. Altshuler, R., "A Dynamic Analysis of the Research and Experimentation Credit," *National Tax Journal* 41(4):453-466, 1988.
6. Altshuler, R., Professor, Department of Economics, Columbia University, New York, NY, personal communication, November 26, 1990.
7. Altshuler, R., and Chaoul, H., "The Effect of Tax Policy on Returns to R&D in the Pharmaceutical Industry: A Methodological Review," contract report prepared for the Office of Technology Assessment, U.S. Congress, November 1990.
8. American Home Products Corporation, Annual Report, Filing With the U.S. Securities and Exchange Commission, Washington, DC, 1988.
9. American Medical Association, "Impact of Product Liability on the Development of New Medical Technologies," *Proceedings of the House of Delegates, 137th Annual Meeting*, Chicago, IL, June 26-30, 1988.
10. American Medical Association Council on Scientific Affairs and Council on Ethical and Judicial Affairs, "Conflicts of Interest in Medical Center/Industry Research Relationships," *Journal of the American Medical Association* 263:2790-2793, 1990.
11. Arnemick, B. A., *Patent Law for the Nonlawyer: A Guide for the Engineer, Technologist, and Manager* (New York, NY: Van Nostrand Reinhold Co., 1986).
12. *Amgen, Inc. v. Chugai Pharmaceutical Co.*, 927 F. 2nd 153214 (Fed. Cir. 1990).
13. *Amgen, Inc. v. International Trade Commission*, 902 F. 2nd 153214 (Fed. Cir. 1990).
14. Anderson, W. F., "Whither Goest Thou, Gene Therapy?" *Human Gene Therapy* 1:227-228, 1990.
15. Anderson, W. F., "End-of-the-Year Potpourri," *Human Gene Therapy* 2:299-300, 1991.
16. Anderson, W. F., Blaese, R. M., and Culver, K., "The ADA Human Gene Therapy Clinical Protocol," *Human Gene Therapy* 1:331-362, 1990.
17. Andersson, F., Research Scientist, Battelle Medtap, London, United Kingdom, personal communication, April 1, 1992.
18. Aronson, N., Technology Manager, Blue Cross/Blue Shield Association, Chicago, IL, personal communication, October 9, 1991.
19. Arrow, K., "Economic Welfare and the Allocation of Resources for Invention," *The Rate and Direction of Inventive Activity: Economic and Social Factors*, R.R. Nelson (ed.) (Princeton, NJ: Princeton University Press, 1962).
20. Arthur Andersen and Company, "Executive Summary of the PMA Cost of Regulation Study," *Economic Costs of FDA Regulations*, Pharmaceutical Manufacturers Association, Mon-

- ograph (Washington, DC: Pharmaceutical Manufacturers Association, March 1981).
21. Asbury, C. H., "The Orphan Drug Act: The First Seven Years," *Journal of the American Medical Association* 265:893-897, 1991.
  22. Association of the British Pharmaceutical Industry, *Pharma Facts and Figures* (London, United Kingdom: The Association of the British Pharmaceutical Industry, 1992).
  23. **Baber, W. R.**, Professor, School of Business and Public Administration, George Washington University, Washington, DC, unpublished note to the **Office of Technology** Assessment, U.S. Congress, Washington, DC, July 1991.
  24. **Baber, W.R.**, Professor, School of Business and Public Administration, George Washington University, Washington, DC, personal communication, November 19, 1991,
  25. **Baber, W.R.**, and **Kang, S.-H.**, "An Empirical Investigation of Accounting Rates of Return for the Pharmaceutical Industry 1975 -1987," preliminary draft submitted to the Office of **Technology** Assessment, U.S. Congress, August 1990.
  26. **Baber, W. R.**, and **Kang, S.-H.**, "An Empirical Investigation of Accounting Rates of Return for Pharmaceutical Industry 1975 -87," draft paper prepared for the Office of **Technology** Assessment, U.S. Congress, December 1990.
  27. **Baber, W. R.**, and **Kang, S.-H.**, "Accounting-Based Measures as **Estimates** of Economic Rates of Return: An Empirical Study of the U.S. Pharmaceutical Industry 1976-87," draft paper prepared for the Office of **Technology** Assessment, U.S. Congress, March 1991.
  28. **Baber, W. R.**, and **Kang, S.-H.**, "Accounting-Based Measures as **Estimates** of Economic Rates of Return: An Empirical Study of the U.S. Pharmaceutical **Industry** 1976-87," draft paper prepared for the Office of **Technology** Assessment, U.S. Congress, July 1991.
  29. **Baber, W.R.**, **Ross, R. S.**, and **Apple, J.R.**, "Research and **Development** Accounting Issues With Specific Reference to the U.S. Pharmaceutical Industry," paper prepared for the Office of **Technology** Assessment, U.S. Congress, December 1990.
  30. **Bachynsky, J.**, "**Government** Control of Drug Prices in Canada," paper presented at "Government Influence in Pharmaceutical Pricing: **Lessons** from Home and Abroad," an invitational conference sponsored by the Institute for **Pharmaceutical** Economics, Philadelphia College of Pharmacy Science, Philadelphia, PA, September 26, 1991.
  31. **Bader, F.**, 'Carrying Costs for Biotech Manufacturing Facilities: Impediment to Competitiveness,' Executive Summary, Genetics Institute, Andover, MA, 1992.
  32. **Baily, M. N.**, "Research and Development Costs and Returns: The U.S. Pharmaceutical Industry,' *Journal of Political Economy* 80(1):70-85, 1972.
  33. **Baily, M. N.**, and **Lawrence, R. Z.**, "The Incentive Effects of the New R&D Tax Credit," unpublished manuscript, Brookings Institution, Washington, DC, July 1990.
  34. **Baird, S. J.**, Director of the Bureau of Program Development and Review, New York Elderly Pharmaceutical Insurance Program, Albany, NY, personal communication, October 30, 1991.
  35. **Baker, C.**, and **Kramer, N.**, "Employer-Sponsored Prescription Drug Benefits," *Monthly Labor Review* 114:31-35, 1991.
  36. **Barr Laboratories, Inc.**, Annual Report, Filing With the U.S. Securities and Exchange **Commission**, Washington, DC, 1991.
  37. **Bard, P. E.**, *Fifteen Years of Results in Pharmaceutical Research Throughout the World, 1975-1989* (France: **Fondation Rhone-Poulenc Sante**, August 1990).
  38. **Barton, M.**, Staff Assistant, Vermont Department of Health, **Waterbury, VT**, personal communication, October 28, 1991.
  39. **Baumol, W. J.**, **Heim, P.**, **Malkiel, B. G.**, et al., "Earnings Retention, New Capital and the Growth of the Firm,' *Review of Economics and Statistics* 52:345-355, November 1970; as cited in **Mueller, D. C.**, and **Reardon, E. A.**, "Rates of Return on Corporate Investment," Department of Economics, University of Maryland, College **Park, MD**, undated manuscript.
  40. **Beatrice, M. G.**, Acting Director, Center for **Biologics** Evaluation and Research, Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Service, **Rockville, MD**, personal communications, October 18, 1990, and January 5, 1992.
  41. **Beatrice, M. G.**, "Regulation, Licensing, and Inspection of Biological Products,' *Pharmaceutical Engineering* 11(3):29-35, May/June 1991.

42. Becker, E. L., Butterfield, W. J. H., Harvey, A. M., et al., *International Dictionary of Medicine and Biology in Three Volumes* (New York, NY: John Wiley and Sons, 1986).
43. Beier, D., Vice President of Government Affairs, and Glick, M., Treasurer, Genentech, Inc., Washington, DC and San Francisco, CA, personal communication, March 11, 1992.
44. Bennett, R. M., Director of Health Audit, National Audit Office, London, United Kingdom, letter to the Office of Technology Assessment, U.S. Congress, Washington, DC, November 29, 1991.
45. Bennett, R. M., Director of Health Audit, National Audit Office, London, United Kingdom, personal communication, October 23, 1992.
46. Berndt, E., and Griliches, Z., "Prices Indexes for Microcomputers: An Exploratory Study," *NBER Working Paper Series*, Working Paper No. 3378, (Cambridge, MA: National Bureau of Economic Research, 1990).
47. Bianucci, D., Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services, Rockville, MD, personal communication, February 5, 1992.
48. Bitz, D. W., Director of Drug Registration and Regulatory Affairs, Sandoz Pharmaceuticals Corp., East Hanover, NJ, personal communication, September 9, 1992.
49. Blaese, R. M., and Anderson, W. F., "The ADA Human Gene Therapy Protocol" [original covering memo] *Human Gene Therapy* 1 :327-329, 1990.
50. Blumenthal, D. B., Epstein, S., and Maxwell, J., "Commercializing University Research: Lesson From the Experience of the Wisconsin Alumni Research Fund," *New England Journal Medicine* 232: 1621-1626, 1986.
51. Blumenthal, D. B., Gluck, M. E., Epstein, S., et al., *University-Industry Relationships in Biotechnology: Implications for Federal Policy*, Final Report to the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services, U.S. DHHS Grant #100A-83, March 20, 1987.
52. Blumenthal, D. B., Gluck, M. E., Louis, K. S., et al., "Industry Support of University Research in Biotechnology: An Industry Perspective," *Science* 231 :242-245, 1986.
53. Blumenthal, D. B., Gluck, M. E., Louis, K.S, et al., "University-Industry Relationships in Biotechnology: Implications for the University," *Science* 232:1361-1366, 1986.
54. Bok, D., "Balancing Responsibility and Innovation," *Change* 14(6):16-25, 1982.
55. Bond, R. S., and Ian, D. F., "Sales, Promotion and Product Differentiation in Two Prescription Drug Markets," Staff Report to the U.S. Federal Trade Commission, Washington, DC, 1977.
56. Botstein, D., White, R. L., Skolnick, M., et al., "Construction of a Genetic Linkage Map in Man Using Restriction Fragment Length Polymorphisms," *American Journal of Human Genetics* 32:314-331, 1980.
57. *Bowsher v. Merck & Co. Inc.*, 103 S. Ct. 1587, 1591 n. 4 (1983).
58. Brauch, S. K., and Casy, A. F., "Applications of High-Field NMR Spectroscopy in Medicinal Chemistry," *Progress in Medicinal Chemistry* 26:355-436, 1989.
59. Brealey, R. A., and Myers, S. C., *Principles of Corporate Finance, 4th Edition* (New York, NY: McGraw-Hill, 1988).
60. *Bristol-Myers Co. v. Staats*, 428 F. Supp. 1388 (1977) *aff'd per curiam* 620 F. 2d. 17 (2nd Cir. 1980), *aff'd mem. by equally divided Court* 451 U.S. 400 (1981).
61. Brody, M., "When Products Turn Into Liabilities," *Fortune* 113:20-24, March 3, 1986.
62. Brownlee, O. H., "The Economic Consequences of Regulating Without Regard to Economic Consequences," *Issues in Pharmaceutical Economics*, R.A. Chien (ed.)(Lexington, MA: D.C. Heath and Company, 1979); as cited in Jensen, E.J., "Rates of Return to Investment in the Pharmaceutical Industry: A Survey," contract paper prepared for the Office of Technology Assessment, U.S. Congress, September 1990.
63. Burlington, D. B., remarks at "Drug Approvals in the United States and Abroad," seminar sponsored by the Institute for Alternative Futures Foresight, Washington, DC, October 7, 1991.
64. Burrill, S., and Lee, K., *Biotech 91, Changing Environment: An Industry Annual Report* (San Francisco, CA: Ernst & Young, 1990).
65. Burrill, S., and Lee, K., *Biotech 92, Promise to Reality: An Industry Annual Report* (San Francisco, CA: Ernst & Young, 1991).

66. **Burrill, S.**, and **Lee, K.**, *Biotech 93, Accelerating Commercialization: An Industry Annual Report* (San Francisco, CA: Ernst & Young, 1992).
67. **Burstall, M.L.**, "Europe After 1992: Implications for Pharmaceuticals," *Health Affairs* 10(3):157-171, 1991.
68. **Burstall, M.L.**, and **Senior, I.**, *The Community's Pharmaceutical Industry* (Luxembourg, Belgium: Commission on the European Communities, 1985).
69. **Buto, K.**, Director, Bureau of Policy Development, Health Care Financing Administration, U.S. Department of Health and Human Services, Baltimore, MD, personal communication, December 20, 1990.
70. **Califre, R.**, "Marketing Applications in the 1990s, The Paper Dilemma-A Review of Alternative Technologies," conference sponsored by the Drug Information Association, Amsterdam, The Netherlands, November 9-11, 1989.
71. Canadian Drug Manufacturers Association, *The Straight Facts, No. 5*, September 1991, as cited in **Lexchin, J.**, "Pharmaceuticals, Patents and Politics: Canada and Bill C-22," report prepared for the Canadian Centre for Policy Alternatives, Ottawa, Ontario, Canada, February 1992.
72. **Carter, L.**, Special Assistant to the Director, Office of Technology Transfer, National Institutes of Health, Public Health Service, U.S. Department of Health and Human Services, Bethesda, MD, personal communication, February 28, 1991.
73. **Caves, R. E.**, **Whinston, M.D.**, and **Hurwitz, M. A.**, "Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry," *Brookings Papers on Economic Activity Microeconomics: 1991* (Washington, DC: Brookings Institution, 1991).
74. **Chadwick, L. W.**, "Pharmaceutical R&D Study," contract paper prepared for Office of Technology Assessment, U.S. Congress, Washington, DC, December 1989.
75. **Chen, P. S.**, "Testimony on the Commercialization of Federal Laboratory Technology Before the Subcommittee Regulation, Business Opportunities and Energy, Committee on Small Business, House of Representatives, U.S. Congress, Washington, DC, October 5, 1989.
76. **Chen, P. S.**, **Letter** to the Honorable Ronald Wyden, U.S. House of Representatives in response to a request at hearings on October 5, 1989 before the Subcommittee on Regulation, Business Opportunities and Energy, Committee on Small Business, U.S. Congress, November 13, 1989.
77. **Chen, P. S.**, "Testimony on Implementation of the Federal Technology Transfer Act Before the Subcommittee on Science, Research and Technology, Committee on Science, U.S. House of Representatives, U.S. Congress, Washington, DC, May 3, 1990.
78. **Clarkson, K.W.**, *Intangible Capital and Rates of Return* (Washington, DC: American Enterprise Institute, 1977).
79. **Clymer, H.**, "The Changing Costs and Risks of Pharmaceutical Innovation," *Economics of Drug Innovation*, **J.D. Cooper** (ed.) (Washington, DC: The American University, 1969).
80. **Cocks, D.L.**, "Comment on the Welfare Cost of Monopoly: An Inter-Industry Analysis," *Economic Enquiry* 13:601-606, December 1975.
81. **Cohen, Jon**, "Did Liability Block AIDS Trial?" *Science* 257:316-317, July 17, 1992.
82. **Cohen, N.C.**, **Blaney, J.**, **Humblet, C.**, et al., "Molecular Modeling Software and Methods in Medicinal Chemistry," *Journal of Medicinal Chemistry* 33:883-894, 1990.
83. **Coleman, T. S.**, "Waxman-Hatch Exclusivity Provisions Not Related to Patent Status," *Food Drug Cosmetic Law Journal* 46:345-356, 1991.
84. **Collier, J.**, "The Pharmaceutical Price Regulation Scheme: A Time for Change," *The Lancet* 1(8437):862-863, 1985.
85. **Comanor, W. S.**, "Research and Technical Change in the Pharmaceutical Industry," *Review of Economics and Statistics* 47(2):182-190, May 1965.
86. **Comanor, W. S.**, "The Political Economy of the Pharmaceutical Industry," *Journal of Economic Literature* 24:1178-1217, 1986.
87. **Comanor, W. S.**, and **Wilson, T.A.**, *Advertising and Market Power* (Cambridge, MA: Harvard University Press, 1974).
88. Commerce Clearinghouse, *Medicare and Medicaid Guide, 1990* (Chicago, IL: Commerce Clearinghouse, 1990).
89. **Connell, E. B.**, "The Crisis in Contraception," *Technology Review* 90:47-55, May/June, 1987.

90. Consumer and Corporate Affairs Canada, *Compulsory Licensing of Pharmaceuticals: A Review of Section 41 of the Patent Act*, **Canadian** Catalog No. RG 15-2-1983 (Ottawa, Canada: Ministry of Supply and Services Canada, 1983).
91. Cook-Deegan, R. M., "The Genesis of the Human Genome Project," *Molecular Genetic Medicine, Volume 1*, T. Friedmann (ed.) (San Diego, CA: Academic Press, 1991).
92. Cooper, R., "The Rise of Activity Based Costing, Part I," *Journal of Cost Management*, Volume 6, Summer 1988.
93. Cooper, R., "The Rise of Activity Based Costing, Part II," *Journal of Cost Management*, Volume 7, Fall 1988.
94. Cooper, R., "The Rise of Activity Based Costing, Part III," *Journal of Cost Management*, Volume 8, Winter 1989.
95. Cooper, R., "The Rise of Activity Based Costing, Part IV," *Journal of Cost Management* Volume 13, Spring 1990.
96. Copeland, T. E., and Weston, J. F., *Financial Theory and Corporate Policy, 3rd Edition* (Reading, MA: Addison-Wesley Publishing Company, 1988).
97. Coppinger, P., "Overview of the Competitiveness of the U.S. Pharmaceutical Industry," presentation to the Council on Competitiveness Working Group on the Drug Approval Process, Washington, DC, December 12, 1990.
98. Coppinger, P., Deputy Associate Commissioner for Planning and Evaluation, Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services, Rockville, MD, personal communications, December 30, 1991 and January 6, 1992.
99. Coulson, A., Sulston, J., Brenner, S., et al., (eds.) "Toward a Physical Map of the Genome of the Nematode *Caenorhabditis elegans*," *Proceedings of the National Academy of Sciences* (Washington, DC: National Academy of Sciences, 1986).
100. Courteau, J., "Genome Databases," *Science* 254:201-207, 1991.
101. Crawford, S. Y., "ASHP National Survey of Hospital-Based Pharmaceutical Services—1990," *American Journal of Hospital Pharmacy* 47:2655-2695, 1990.
102. Dasgupta, P., and Stiglitz, J., "Uncertainty Industrial Structure, and the Speed of R&D," *Bell Journal of Economics* 11:1-28, 1980.
103. Davis, H. J., "The Shield Intrauterine Device," *American Journal of Obstetrics and Gynecology* 106(3):455-456, 1970.
104. *Davis v. Wyeth Laboratories*, 399 F. 2d 121 (9th Cir. 1968).
105. Dean, P. M., *Molecular Foundations of Drug-Receptor Interactions* (New York, NY: Cambridge University Press, 1987).
106. DiMasi, J. A., Research Associate, Center for the Study of Drug Development, Tufts University, Boston, MA, personal communications, November 3, 1992, September 1992, April 14, 1992, July 1991, and October 18, 1990.
107. DiMasi, J. A., Bryant, N. R., Lasagna, L., "New Drug Development in the United States, 1963-1990," *Clinical Pharmacology and Therapeutics* 50(5):471-486, 1991.
108. DiMasi, J. A., Bryant N. R., and Lasagna L., "Success Rates for New Chemical Entities (NCEs) Entering Clinical Testing in the United States," Poster Presentation, American Society for Clinical Pharmacology Annual Meetings, Orlando, FL, March 20, 1992.
109. DiMasi, J.A., Hansen, R.W., Grabowski, H. G., et al., "The Cost of Innovation in the Pharmaceutical Industry," *Journal of Health Economics* 10:107-142, 1991.
110. Donis-Keller, H., Green, P., Helms, C., et al. (eds.), "A Genetic Linkage Map of the Human Genome," *Cell* 51:319-337, 1987.
111. Doolittle, R. F., Hunkapiller, M. W., Hood, L. E., et al., "Simian Sarcoma virus *onc* gene, *v-sis*, Is Derived From the Gene (or Genes) Encoding a Platelet-Derived Growth Factor," *Science* 221:275-277, 1983.
112. Dranove, D., and Meltzer, D., "Does the FDA Accelerate or Delay the Approval of Important Drugs?" unpublished manuscript, Northwestern University and University of Chicago, Evanston IL, December 1991.
113. DuBose, M., and Moore, S.D., "Speedy Global Approval in Drug Tests Won't Be Implemented for Many Years," *The Wall Street Journal*, November 15, 1991, p. B5.
114. Dukes, G., *The Effects of Drug Regulations* (Lancaster, United Kingdom: MTP Press Ltd., 1985).

115. Dungworth, T., *Product Liability and the Business Sector: Litigation Trends in Federal Courts* (Santa Monica, CA: The Rand Corporation, 1988).
116. Eastep, R., Deputy Director, Division of Biological and Investigational New Drugs, Center for Biologics Evaluation and Research, Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services, Rockville, MD, personal communication, October 10, 1990.
117. *The Economist*, "A Tighter Prescription," *The Economist* 312(622):61-62, 1989.
118. Eisman, M.M., and Warden, W. M., "Incremental Time Study: An Analysis of Time Spent in the Development and Approval of Drugs for the U.S. Market," *Economic Costs of FDA Regulations*, Pharmaceutical Manufacturers Association (ed.) (Washington, DC: Pharmaceutical Manufacturers Association, 1981).
119. Eisner, R., Albert, S.H., and Sullivan, M.A., "The New Incremental Tax Credit for R&D: Incentive or Disincentive," *National Tax Journal* 37:171-183, June 1984.
- 119a. Eli Lilly and Company, Annual Reports, Filing With the U.S. Securities and Exchange Commission, Washington, DC, 1987, 1988, 1989.
120. Eli Lilly, *Lilly Hospital Pharmacy Survey* (Indianapolis, IN: Eli Lilly & Co., 1991).
121. Eli Lilly & Co., "Eli Lilly and Company and Centocor, Inc., Form Strategic Alliance," July 16, 1992 [press release].
122. *Eli Lilly & Co. v. Staats*, 574 F.2d. 904,923 (7th Cir. 1978) cert. den. 439 US 959,99 S. Ct. 362 (1978).
123. Engelberg, A. B., "Patent Term Extension: An Overreaching Solution to a Nonexistent Problem," *Health Affairs* 1(1):34-45, 1982.
124. Engelberg, A. B., Attorney in private practice, Greenwich, CT", personal communications, February 26, 1991 and May 13, 1992.
125. Evans, D., Health Economist, Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland, personal communication, April 1 and 2, 1992.
126. Executive Office of the President, Office of Management and Budget, *Standard Industrial Classification Manual* (Washington, DC: U.S. Government Printing Office, 1972).
127. *F-D-C Reports: Health News Daily*, "FDA Changes Rating System for Drugs," *F-D-C Reports: Health News Daily*, January 7, 1992, p. 3.
128. *F-D-C Reports: Prescription and OTC Pharmaceuticals*, "Mail Order Grew 37% to \$2.9 Bil. in 1991 IMS Survey; Growth May Slow Soon," *F-D-C Reports: Prescription and OTC Pharmaceuticals*, March 16, 1992, p. 11.
- 128a. Faich, G., "Adverse Drug Reaction Monitoring," *New England Journal of Medicine* 314(24): 1589-1592, 1986.
129. Fama, E.F., and French, K.R., "The Cross-Section of Expected Stock Returns," Working Paper, Center for Research in Security Prices, Graduate School of Business, University of Chicago, Chicago, IL, January 1992.
130. Farley, P. J., *Private Health Insurance in the U.S. Data Preview #23*, DHHS Publication No. (PHS) 86-3406 (Washington, DC: U.S. Department of Health and Human Services, National Center for Health Services Research and Health Care Technology Assessment, September 1986).
131. Fein, R., "Economics of Health Research," *Horizons of Health*, H. Wechsler, J. Gurin, and G. Cahill (eds.) (Cambridge MA: Harvard University Press, 1977).
132. Fisher, F. M., and McGowan, J.J., "On the Misuse of Accounting Rates of Return to Infer Monopoly Profits," *American Economic Review* 73(1):82-97, 1983.
133. Flamm, W. G., and Farrow, M., "Recent Trends in the Use and Cost of Animals in the Pharmaceutical Industry," paper prepared for the Office of Technology Assessment, U.S. Congress, Washington, DC, April 1991.
134. Ford, M., *Medicaid: Reimbursement for Outpatient Prescription Drugs*, Congressional Research Service Report to the U.S. Congress, No. 91-235 EPW (Washington, DC: U.S. Government Printing Office, March 7, 1991).
135. Foster Higgins and Co., *1990 Health Care Benefits Survey. Report 1—Indemnity Plans: Cost Design and Funding* (New York, NY: A. Foster Higgins and Co., Inc., 1991).
136. Frank, R. G., and Salkever, D. S., "Pricing, Patent Loss and the Market for Pharmaceuticals," contract paper prepared for the Office of Technology Assessment, U.S. Congress, Washington, DC, December 1990.

137. Friedland R. B., *Facing the Costs of Long-Term Care: An EBRI-ERF Policy Study* (Washington, DC: Employee Benefit Research Institute, 1990),
138. Fritz, D. L., "Drug Use Review Principles Adopted by Key Organizations," *Journal of the American Association of Preferred Provider Organizations* 1(4):22-26, 1991.
139. Fukushima, M., "The Overdose of Drugs in Japan," *Nature* 342(252):850-851, 1989.
140. Ganellin, C. R., "Cimetidine," *Chronicles of Drug Discovery*, J.S. Bindra, and D. Ledniger (eds.)(New York, NY: Wiley, 1982).
141. Garber, A. M., Clarke, A. E., Goldman, D. P., et al., *Federal and Private Roles in the Development and Provision of Alglucerase Therapy for Gaucher Disease* (Background paper for OTA'S Project on Government Policies and Pharmaceutical Research and Development), prepared for the Office of Technology Assessment, U.S. Congress, OTA-BP-H-104 (Washington, DC: U.S. Government Printing Office, October 1992).
142. Garber, S., Senior Economist, The Rand Corporation, Santa Monica, CA, personal communications, May 30, 1991 and September 17, 1992.
143. Gates, S., Associate Director for the Center of Utilization of Federal Technology, National Technical Information Service, U.S. Department of Commerce, Springfield, VA, personal communication, April 12, 1991.
144. Gaynor, K., Partner, Price Waterhouse, New York, NY, personal communication, April 1992.
145. Genentech, Inc., Annual Report, Filing With the U.S. Securities and Exchange Commission, Washington, DC, 1989.
146. Gibbons, A., "Biotech Pipeline: Bottleneck Ahead," *Science* 254:369-370, 1991.
147. Gladwell, M., "FDA Plans Reforms for Drug Process," *The Washington Post*, November 8, 1991, p. A1, A22.
148. Gladwell, M., "Critics Say New FDA Procedures for Approving Drugs Would Weaken Agency," *The Washington Post*, November 14, 1991, p. A3.
149. Glaser, W. A., Professor, New School for Social Research, Department of Management and Urban Policy, New York, NY, letter to the Office of Technology Assessment, U.S. Congress, Washington, DC, February 9, 1992.
150. Gluck, M. E., *University-Industry Relationships in Biotechnology: Implications for Society*, unpublished doctoral dissertation, Harvard University, Cambridge, MA, 1987.
151. Gluck, M. E., Blumenthal, D. B., and Stoto, M.A., "University-Industry Relationships in the Life Sciences: Implications for Students and Post-Doctoral Fellows," *Research Policy* 16:327-336, 1987.
152. Gogerty, J., "Preclinical Research Evaluation: Pharmacology; Toxicology; Drug Metabolism," *New Drug Approval Process: Clinical and Regulatory Management*, RA. Guarino (ed.)(New York, NY: Marcel Dekker, Inc., 1987).
153. Grabowski, H., "Medicaid Patients' Access to New Drugs," *Health Affairs* 7:102-114, Winter 1988.
154. Grabowski, H., Professor, Department of Economics, Duke University, Durham, NC, personal communication, July 15, 1992.
155. Grabowski, H.G., and Mueller, D. C., "Life Cycle Effects on Corporate Investment," *Review of Economics and Statistics* 57:400-409, November 1975; as cited in Mueller, D. C., and Reardon, E. A., "Rates of Return on Corporate Investment," Department of Economics, University of Maryland, College Park, MD, undated manuscript.
156. Grabowski, H. G., Schweitzer, S.O., and Shiota, R., "The Medicaid Drug Lag Adoption of New Drugs by State Medicaid Formulas," unpublished paper, Durham, NC, July 1990.
157. Grabowski, H. G., and Vernon, J. M., "A Sensitivity Analysis of Expected Profitability of Pharmaceutical Research and Development," *Managerial and Decision Economics* 3(1):36-40, 1982.
158. Grabowski, H. G., and Vernon, J. M., "Pioneers, Imitators, and Generics-A Simulation Model of Schumpeterian Competition," *Quarterly Journal of Economics* 102(3):491-525, 1987.
159. Grabowski, H.G., and Vernon, J. M., "A New Look at the Returns and Risks to Pharmaceutical R&D," *Management Science* 36(7):804-821, July 1990.
160. Grabowski, H. G., and Vernon, J. M., unpublished appendix to "A New Look at the Returns and Risks to Pharmaceutical R&D," Department of Economics, Duke University, Durham, NC, 1990.

161. **Grabowski, H.G.**, and **Vernon, J.M.**, "Brand Loyalty, Entry and Price Competition in Pharmaceuticals After the 1984 Drug Act," *Journal of Law and Economics* 35(2):331-350, October 1992.
162. **Grabowski, H. G.**, **Vernon, J. M.**, and **Thomas, L. G.**, "Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry," *The Journal of Law and Economics* 21(1):133-163, 1978.
163. **Graig, L. A.**, *Health of Nations* (Washington, DC: The Wyatt Company, 1991).
164. **Graves, E. J.**, and **Kozak, L. J.**, *National Discharge Survey: Annual Summary, 1989* (Vital Health Stat 13 (109)), DHHS No.(PHS) 92-1770 (Hyattsville, MD: National Center for Health Statistics, March 1992).
165. **Griffin, M.E.**, **Ray, W. A.**, **Mortimer, E.A.**, et al., "Risk of Seizures and **Encephalopathy** After Immunization With the **Diphtheria-Tetanus-Pertussis Vaccine**," *Journal of the American Medical Association* 263(12):1641-1645, 1990.
166. **Griliches, Z.**, "Search for R&D Spillovers," National Bureau of Economic Research, reprint 1758, 1992.
167. **Groft, S.**, Acting Director, Office of Science Policy and **Legislation**, National Institutes of Health, Public Health Service, U.S. Department of Health and Human Services, Bethesda, MD, personal communication, February 8, 1991.
168. **Haffner, M. E.**, and **Kelsey, J.V.**, "Evaluation of Orphan Products by the U.S. Food and Drug Administration," *Inter-national Journal of Technology Assessment in Health Care*, 1992.
169. **Hagan, C. F.**, "Vaccine Compensation Schemes," *Food Drug Cosmetic Law Journal* 45:477-486, 1990.
170. **Hall, B.H.**, "Investment and Research and Development at the Firm Level: Does the Source of Financing Matter?" NBER Working Paper Series, Working Paper No. 4096 (Cambridge, MA: National Bureau of Economic Research, June 1992).
171. **Hall, S. S.**, *Invisible Frontiers: The Race to Synthesize a Human Gene* (New York, NY: Atlantic Monthly Press, 1987).
172. **Halliday, R.**, **Lumley, C.**, and **Walker, S.**, *Trends in Worldwide Pharmaceutical R&D Expenditure in the 1980s* (Surrey, England: Centre for Medicines Research, 1991).
173. **Halperin, J.**, remarks at "Advisory Committees and the FDA," conference sponsored by the Food and Drug Law Institute, Washington, DC, March 15, 1990.
174. **Hancher, L.**, "Regulating Pharmaceutical Prices and Corporate R&D Strategies in Britain and France," *Strategies for New Technology-Case Studies From Britain and France*, M. Sharp and P. Holmes (eds.)(New York, NY: Philip Allan, 1989).
175. **Hansen, R.**, "The Pharmaceutical Development Process: Estimates of Development Costs and Times and the Effect of Proposed Regulatory Changes," *Issues in Pharmaceutical Economics*, **R.A. Chien** (ed.)(Lexington, MA: D.C. Heath and Company, 1979).
176. **Hansen, R.**, Associate Dean, School of Business Administration, University of Rochester, Rochester, NY, personal communication, May 1, 1991.
177. **Hansen, R. W.**, "Effects of Incremental Costs on Pharmaceutical Innovation," *Economic Costs of FDA Regulations*, Pharmaceutical Manufacturers Association (ed.)(Washington, DC: Pharmaceutical Manufacturers Association, 1981).
178. **Harvey, K.**, "Australia: Pharmaceutical Benefits Scheme," *The Lancet* 337(738):418-419, 1991.
179. **Hausch, C.**, and **Blaney, J.M.**, "The New Look to QSAR' *Drug Design: Factor Fantasy?* G. Jones and **K.R.H. Woolridge** (eds.)(New York, NY: Academic Press, 1984).
180. **Hawkins, E. S.**, and **Reich, M.R.**, "Japanese-Originated pharmaceutical Products in the United States from 1960 to 1989: An Assessment of Innovation," *Clinical Pharmacology and Therapeutics* 51(1):1-11, 1992.
181. **Hazelwood, M.**, Manager of Ancillary and Pharmacy Sections, Medical Program, Illinois Department of Public Aid, **Springfield, IL**, personal communication, November 1, 1991.
182. **Henderson, J. A.**, and **Eisenberg, T.**, "The Quiet Revolution in Products Liability: An Empirical Study of Legal Change," *UCLA Law Review* 37:479-553, 1990.
183. **Hendrickson, W. A.**, "Determination of Macromolecular Structures Form Anomalous **Diffraction**

- tion of Synchrotron Radiation,' *Science* 254:5 1-58, 1991.
184. Hensler, D. R., Vaiana, M. E., Kakalik, J. S., et al., *Special Report—Trends in Tort Litigation: The Story Behind the Statistics* (Santa Monica, CA: The Rand Corporation, 1987).
  185. *Hewlett Packard Company v. United States*, 385 F. 2d, 1013 (9th Cir. 1967) cert. denied 390 U.S. 988, 88 S. Ct. 1184 (1968).
  186. Hill, D., and Beatrice, M. G., "Biotechnology Facility Requirements, Part I," *BioPharm*, October 1989, pp. 20-31.
  187. Hilts, P. J., "Top FDA Staff Members Oppose Looser Drug Approval System," *The New York Times*, December 20, 1991, p. A29.
  188. Hilts, P. J., "Seeking Limits to a Drug Monopoly," *New York Times* May 14, 1992, p. D1.
  189. Himmelberg, C. P., and Peterson, B. C., "R&D and Internal Finance: A Panel Study of Small Firms in High-Tech Industries," unpublished manuscript, Washington University, St. Louis, MO, July 10, 1992.
  190. Hollenberg, M. D., "Receptor Triggering and Receptor Regulation: Structure Activity Relationships From the Receptor's Point of View," *Journal of Medicinal Chemistry* 33:1275-1281, 1990.
  191. Hopper, D., Pharmacy Specialist, Maine Bureau of Medical Services, Augusta, ME, personal communication, October 29, 1991.
  192. Huber, P. W., *Liability: The Legal Revolution and Its Consequences* (New York, NY: Basic Books, 1988).
  193. Huber, P.W. and Litan, R.E. (eds.), *The Liability Maze: The Impact of Liability Law on Safety and Innovation* (Washington, DC: The Brookings Institution, 1991).
  194. *Human Gene Therapy*, "Human Gene Transfer/Therapy Patient Registry-Summary," *Human Gene Therapy* 3:457, 1992.
  195. Hurwitz, M. A., and Caves, R. E., "Persuasion or Information? Promotion and the Shares of Brand Name and Generic Pharmaceuticals," *Journal of Law and Economics* 31:299-320, 1988.
  196. Hutt, P. B., "Investigations and Reports Respecting FDA Regulation of New Drugs (Part I)," *Clinical Pharmacology and Therapeutics* 33(4):537-548, April 1983.
  197. Hutt, P. B., "Investigations and Reports Respecting FDA Regulation of New Drugs (Part II)," *Clinical Pharmacology and Therapeutics* 33(5), May 1983.
  198. Ibbotson, R. G., and Sinquefeld, R. A., "Stocks, Bonds, Bills, and Inflation: Simulations of the Future (1976-2000)," *Journal of Business* 49:313-338, July 1976.
  199. Ijiri, Y., "Convergence of Cash Recovery Rate," *Quantitative Planning and Control*, Y. Ijiri, and A. Whinston (eds.) (New York, NY: Academic Press, 1979).
  200. Ijiri, Y., "Recovery Rate and Cash Flow Accounting," *Financial Executive* 48:54-60, March 1980.
  201. IMS America, Inc., unpublished data prepared for the Office of Technology Assessment, U.S. Congress, Washington, DC, 1991.
  202. Ingersoll, B., "Drug Approvals to be Hastened Under New Pact," *The Wall Street Journal*, November 13, 1991, p. A3.
  203. Ingersoll, B., and Stout, H., "Plan to Reform Drug Approvals Has Opposition," *The Wall Street Journal*, November 14, 1991, p. B4.
  204. *Inside Roche*, "The Animal Research Debate: Is There a Common Ground?" *Inside Roche* 13:2-11, 1989.
  205. Institute of Management Accountants, *Management Accounting Glossary* (Englewood Cliffs, NJ: Prentice Hall, 1991).
  206. Institute of Medicine, *Vaccine Supply and Innovation* (Washington, DC: National Academy Press, 1985).
  207. Institute of Medicine, *Funding Health Sciences Research: A Strategy to Restore Balance* (Washington, DC: National Academy Press, 1990).
  208. Institute of Medicine, *The AIDS Research Program of the National Institutes of Health: Report of a Study* (Washington, DC: National Academy Press, 1991).
  209. Interstudy, *Managed Care: A Decade in Review, 1980-1990* (Excelsior, MN: Interstudy, 1991).
  210. James, B. E., remarks at 'Drug Approvals in the U.S. and Abroad,' seminar sponsored by the Institute for Alternative Futures, Washington, DC, October 7, 1991.
  211. Japanese Pharmaceutical Affairs Bureau, *Pharmaceutical Administration in Japan, 5th Edition* (Tokyo, Japan: Yakuji Nippo, Ltd., 1991).

212. Japan Pharmaceutical Manufacturers Association, *Data Book 1990* (Tokyo, Japan: Japan Pharmaceutical Manufacturers Association, 1990)
213. Jensen, E. J., "Research Expenditures and the Discovery of New Drugs," *Journal of Industrial Economics* 36(1):83-95, 1987.
214. Jensen, E. J., "Rates of Return to Investment in the Pharmaceutical Industry: A Survey," contract paper prepared for the Office of Technology Assessment, U.S. Congress, Washington, DC, September 1990.
215. **Joglekar, P.**, and Paterson, M. L., "A Closer Look at the Returns and Risks of Pharmaceutical R&D," *Journal of Health Economics* 5:153-177, 1986.
216. Johnson, H. T., and Kaplan, R. S., *Relevance Lost: The Rise and Fall of Management Accounting* (Cambridge, MA: Harvard Business Review, 1987).
217. Jones, G., "Conclusions," *Drug Design: Fact or Fantasy?* G. Jones and K.R.H. Woolridge (eds.) (New York, NY: Academic Press, 1984).
218. Jones, T.M., "Improved Drug Delivery: A Perspective From Industry," *Novel Drug Delivery and Its Therapeutic Application*, L.F. Prescott and W.S. Nimmo (eds.) (New York, NY: Wiley, 1989),
219. Kahn, H. A., and Sempos, C.T., *Statistical Methods in Epidemiology* (New York, NY: Oxford University Press, 1989).
220. **Kaitin, K. I.**, Mathison, N., Worthington, F. K., et al., "The Drug Lag: An Update of New Drug Introductions in the U.S. and U.K., 1977 through 1987," *Clinical Pharmacology and Therapeutics* 4:121-138, 1989.
221. **Kaitin, K. I.**, Melville, A., and Morris, B., "FDA Advisory Committees and the New Drug Approval Process," *Journal of Clinical Pharmacology* 29(10):886-890, 1989.
222. Kamien, M. I., and Schwartz, N. L., *Market Structure and Innovation* (Cambridge, NY: Cambridge University Press, 1982).
223. Kang, S.-H., Assistant Professor, School of Industrial Administration, Carnegie-Mellon University, Pittsburgh, PA, unpublished note to the Office of Technology Assessment, U.S. Congress, Washington, DC, July 1991.
224. Kang, S.-H., Assistant Professor, School of Industrial Administration, Carnegie-Mellon University, Pittsburgh, PA, personal communication, November 19, 1991.
225. Kaplan, E. L., and Meier, P., "Nonparametric Estimation From Incomplete Observations," *Journal of the American Statistical Association* 53(282):457, 1958.
226. Katz, M., "The Birth Pangs of a New Drug," *Drug and Cosmetic Industry* 128:40, October 1980; as cited in Smith, M., *Principles of Pharmaceutical Marketing* (Philadelphia, PA: Lea & Febiger, 1983).
227. **Kelsey, J.**, Special Assistant to the Director, Office of Orphan Products Development, Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services, personal communications, November 26, 1987, November 26, 1990, and May 10, 1991.
228. Kenney, M., *Biotechnology: The University-Industrial Complex* (New Haven, CT: Yale University Press, 1986).
229. Kerem, B.-S., Rommens, J.M., Buchanan, J.A., et al., "Identification of the Cystic Fibrosis Gene: Genetic Analysis," *Science* 245:1073-1080, 1990.
230. **Kevles, D.J.**, *The Name of Eugenics* (Berkeley, CA: University of California Press, 1985).
231. Keystone AIDS Vaccine Liability Project, *Find Report* (Keystone, CO: The Keystone Center, May 1990).
232. Kiser, J. D., "Legal Issues Raised by Expedited Approval of, and Expanded Access to, Experimental AIDS Treatments," *Food Drug Cosmetic Law Journal* 45(4):363-376, 1990.
233. **Klynveld Peat MarWick Goerdeler (KPMG)**, *Tax Treatment of Research and Development Expenditures* (Amsterdam, The Netherlands: International Tax Center, 1990).
234. Krinsky, S., "Corporate Academic Ties in Biotechnology: A Report on Research in Progress," *GeneWatch* 1:3-5, 1984.
235. **Kuhlik, B.E.**, "The Medicaid Prescription Drug Rebate and Improved Access to Medicines Requirements of the Omnibus Budget Reconciliation Act of 1990," *Food Drug Cosmetic Law Journal* 46:363-390, March 1991.
236. **Kuhlik, B. N.**, and Kingham, R.F., "The Adverse Effects of Standardless Punitive Damage Awards on Pharmaceutical Development and

- Availability,” *Food Drug Cosmetic Law Journal* 45:693-708, 1990.
237. La Pre, E., Eligibility Technician, Rhode Island Department of Elderly Affairs, Providence, RI, personal communication, October 28, 1991.
  238. Laetz, T., and Silberman, G., “Reimbursement Policies Constrain the Practice of Oncology,” *Journal of the American Medical Association* 266:2996-3000, 1991.
  239. Lasagna, L., “The Chilling Effect of Product Liability on New Drug Development,” *The Liability Maze: The Impact of Liability Law on Safety and Innovation*, R.E. Litan and Peter W. Huber (eds.) (Washington, DC: The Brookings Institution, 1991).
  240. Lawton, S. “Controversy Under the Orphan Drug Act: Is Resolution on the Way?” *Food Drug Cosmetic Law Journal* 46:327-343, 1991.
  241. Leonard, H. B., *Checks Unbalanced: The Quiet Side of Government Spending* (New York, NY: Basic Books, 1986).
  242. Levin, R. C., Klevorick, A. K., Nelson, R. R., et al., “Appropriating the Returns From Industrial Research and Development,” *Brookings Papers on Economic Activity* 3:783-820, 1987; as cited in Scherer, F. M., and Ross, D., *Industrial Market Structure and Economic Performance*, 3rd Edition (Boston, MA: Houghton Mifflin Company, 1990).
  243. Lewent, J., Chief Financial Officer, Merck & Co., Rahway, NJ, personal communication, September 8, 1992.
  244. Lexchin, J., “Pharmaceuticals, Patents and Politics: Canada and Bill C-22,” report prepared for the Canadian Centre for Policy Alternatives, Ottawa, Ontario, Canada, February 1992.
  245. Link, A., “Tax Incentives and the U.S. Pharmaceutical Industry,” contract report prepared for the Office of Technology Assessment, U.S. Congress, Washington, DC, November 1990.
  246. Lipenta, C., Human Resources Manager, The Nemours Foundation, Jacksonville, FL, personal communication, November 1, 1991.
  247. Litan, R. E., Swire, P., and Winston, C., “The U.S. Liability System: Background and Trends,” *Liability: Perspectives and Policy*, R.E. Litan and C. Winston (eds.) (Washington, DC: The Brookings Institution, 1988).
  248. Loss, I.S., and Morgenstern, AD., *Pharmaceuticals/Tax Policy: A Successful Puerto Rican Statehood Initiative Will Result in Higher Corporate Tax Rates for Many Companies* (Washington, DC: The NatWest Investment Banking Group, 1990).
  249. Louis, K. S., Swazey, J. P., and Anderson, M. S., “University Policies and Ethical Issues in Graduate Research and Education: Results of a Survey of Graduate School Deans,” unpublished manuscript, University of Minnesota, St. Paul, and Acadia Institute, Bar Harbor, ME, 1991.
  250. Maedgen, B. J., and McCall, S. L., “A Survey of Law Regarding the Liability of Manufacturers and Sellers of Drug Products and Medical Devices,” *St. Mary’s Law Journal* 18:395-462, 1986.
  251. Mahoney, R. J., and Littlejohn, S. E., “Innovation on Trial: Punitive Damages Versus New Products,” *Science* 246:1395-1399, 1989.
  252. Mains, M., Manager, ConnPACE, Connecticut Department of Aging, Hartford, CT, personal communication, October 30, 1991.
  253. Mansfield, E., “Academic Research and Industrial Innovation,” *Research Policy* 20:1-12, 1991.
  254. Marcus, L. C., “Liability for Vaccine-Related Injuries,” *New England Journal of Medicine* 318:191, 1988.
  255. Marks, E., Vice-President, Medco Containment Services, Inc., Montvale, NJ, personal communication, October 27, 1992.
  256. Marks, L., Staff Specialist for pharmacy Services, Maryland Department of Health and Mental Hygiene, Baltimore, MD, personal communication, October 28, 1991.
  257. Marovelli, F. D., *Effective Corporate Tax Rates 1987* (Arlington, VA: Tax Analysts, Inc., 1988).
  258. Marovelli, F. D., Accounting Manager, Tax Analysts, Inc., Arlington, VA, personal communication, April 2, 1992.
  - 258a. MarWick, C., “FDA Seeks Swifter Approval of Drugs for Some Life-Threatening or Debilitating Diseases,” *Journal of the American Medical Association* 260(20):2976, 1988.
  259. Mason, C., Supervising Administrative Analyst, New Jersey Bureau of Pharmaceutical Assistance, Trenton, NJ, personal communication, October 28, 1991.

260. Mattison, N., **Trimble**, A. G., and Lasagna, L., "New Drug Development in the United States, 1963 Through 1984," *Clinical Pharmacology and Therapeutics* **43:290-301**, 1988.
261. Mayr, E., *The Growth of Biological Thought: Diversity, Evolution, and Inheritance* (Cambridge: Harvard University Press, 1982).
262. McAvoy, K., Chief, Economic Assessment Group, Food and Drug Administration, Public Health Services, U.S. Department of Health and Human Services, **Rockville**, MD, personal communication, October 1990.
263. McDonough, R. T., Public Policy Director, The UpJohn Company, Kalamazoo, MI, personal communication, September 8, 1992.
264. McGraw-Hill and Company, *McGraw-Hill Encyclopedia of Science and Technology*, Volume 13 (New York, NY: McGraw-Hill and Company, 1987).
265. **McGuire**, E.P., *The Impact of Product Liability*, Research Report 908 (New York, NY: The Conference Board, 1988).
266. **McKusick**, V. A., *Mendelian Inheritance in Man* (Baltimore, MD: Johns Hopkins University Press, 1990).
267. Merck & Co., Inc., *The Merck Index: An Encyclopedia of Chemicals, Drugs and Biologicals* (**Rahway**, NJ: Merck & Company, 1989).
268. *Merck v. Staats*, 529 F. Supp. 1 (**D.D.C.** 1977) *aff'd per curiam Merck Co. v. Staats*, 665 F.2d 1236 (**D.C.** Cir. 1981).
269. Meyers, A., Chief, Document and Reporting Branch, Office of Drug Evaluation and Research, Center for Drug Evaluation and Research, Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services, **Rockville**, MD, personal communication, April 13, 1990.
270. Meyers, A. S., Executive Director, National Organization for Rare Disorders, Inc., New Fairfield, **CT**, personal communication, August 31, 1992.
271. **Milhous**, W. K., Walter Reed Army Medical Center, Washington, DC, personal communication, October 29, 1991.
272. **Milhous**, W., and **Shuster**, B., "New Drugs for Multiple Drug Resistant Malaria," *U.S. Medicine* **26(15/16):27**, 1990.
273. Miller, M., "Debt and Taxes," *Journal of Finance* **32:261-275**, 1977.
274. **Millstein**, L.G., "Preparing a New Drug Application: General Considerations," *New Drug Approval Process: Clinical and Regulatory Management*, **R.A. Guarino** (ed.) (New York, NY: **Marcel Dekker, Inc.**, 1987).
275. **Millstein**, L. G., "Specific Requirements, Content, and Format of an NDA," *New Drug Approval Process: Clinical and Regulatory Management*, **R.A. Guarino** (ed.) (New York, NY: **Marcel Dekker, Inc.**, 1987).
276. **Mitsuya**, H., **Weinhold**, K., **Yarchoan**, R., et al., "Credit Government Scientists with Developing Anti-AIDS Drug," Letter to the editor, *New York Times*, September 28, 1989, p. A26.
277. **Moeller**, J., and **Lair**, T., *Prescribed Medicines: A Summary of Use, Expenditures, and Source of Payment*, U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy, and Research, tabulations, **Rockville**, MD, forthcoming.
278. **Moertel**, C. G., "Off-Label Drug Use for Cancer Therapy and National Health Care Priorities," *Journal of the American Medical Association* **266:3031-3032**, 1991.
279. Montgomery, A. B., "How the Recent Changes in Expedited Drug Approval Procedures Affect the Work of a Clinical Investigator," *Food Drug Cosmetic Law Journal* **45(4):339-346**, 1990.
280. Montgomery, D., and **Silk**, A., "Estimating Dynamic Effects of Market Communications Expenditures," *Management Science* **18(10):B485-B501**, June 1972.
281. **Moonen**, C.T.W., **van Zijl**, P. C. M., **Frank**, J.A., et al., "Functional Magnetic Resonance Imaging in Medicine and Physiology," *Science* **250:53-61**, 1990.
282. **Mueller**, D. C., and **Reardon**, E.A., "Rates of Return on Corporate Investment," Department of Economics, University of Maryland, College Park, MD, undated manuscript.
283. **Mullis**, K. B., "The Unusual Origin of the Polymerase Chain Reaction," *Scientific American* **262:56-65**, 1990.
284. **Myers**, J. S., Director, Office of Electronic Information Products and Services, U.S. Patent and Trademark Office, U.S. Department of

- Commerce, personal communications, February 8, 1990 and April 4, 1990.
285. Myers, S. C., and Shyarn-Sunder, L., "Cost of Capital Estimates for Investment in Pharmaceutical Research and Development," contract report prepared for the Office of Technology Assessment, U.S. Congress, Washington, DC, January 1991.
  286. Narin, F., and Rozek, R. P., "Bibliometric Analysis of U.S. Pharmaceutical Industry Research Performance," *Research Policy* 17:139-154, 1988.
  287. National Pharmaceutical Council, *Pharmaceutical Benefits Under State Medical Assistance Programs* (Reston, VA: National Pharmaceutical Council, Inc., September 1991).
  288. National Research Council and Institute of Medicine, *Developing New Contraceptives: Obstacles and Opportunities*, L. Mastroianni, P.J. Donaldson, and T.J. Kane (eds.) (Washington, DC: National Academy Press, 1990).
  289. National Science Board, *Science and Engineering Indicators-1989*, NSB Pub. No. 89-1 (Washington, DC: U.S. Government Printing Office, 1989).
  290. National Science Foundation, *Selected Data on Research and Development in Industry: 1990*, Selected Data Tables, NSF 92-317 (Washington, DC: National Science Foundation, 1992).
  291. National Wholesalers and Distributors Association, 1989 *Operating Survey*, (Washington, DC: National Wholesalers and Distributors Association, 1990).
  292. Nelson, C., Survey Statistical, U.S. Income and Statistics Branch, Census Bureau, U.S. Department of Commerce, Washington, DC, personal communication, March 26, 1991.
  293. Neustadt, R. E., and Fineberg, H., *The Epidemic That Never Was: Policy-Making and the Swine Flu Affair* (New York, NY: Vintage Books, 1982).
  294. Newhouse, J. P., Manning, W. G., Morris, C. N., et al., "Some Interim Results From a Controlled Trial of Cost Sharing in Health Insurance," *New England Journal of Medicine* 305:1501, 1981.
  295. Norton, N. N., "Exploring Europe's Generics Market," *Pharmaceutical Executive* 11(9):46-56, 1991.
  296. Oestreicher, P., Assistant Director of Public Policy and Communications, Hoffmann-La Roche, Inc., Nutley, NJ, letter to the Office of Technology Assessment, U.S. Congress, Washington, DC, June 22, 1992.
  297. O'Hare, J., Economist, Joint Committee on Taxation, U.S. Congress, Washington, DC, personal communication, December 19, 1990.
  298. Olson, M., "Pharmaceutical Firm R&D Strategy," working paper, Department of Economics, Washington University, St. Louis, MO, September 1992.
  299. Olson, M. V., Dutchik, J. E., and Graham, M. Y., "Random-Clone Strategy for Genomic Restriction Mapping in Yeast," *Proceedings of the National Academy of Sciences* (Washington, DC: National Academy of Sciences, 1986).
  300. Ondetti, M. A., Cushman, D. W., and Rubin, B., "Captopril," *Chronicles of Drug Discovery*, J.S. Bindra and D. Ledniger (eds.) (New York, NY: Wiley, 1983).
  301. O'Reilly, B., "Drugmakers Under Fire," *Fortune* 124:48-61, July 29, 1991.
  302. Organisation for Economic Co-operation and Development, *The Pharmaceutical Industry: Trade Related Issues* (Paris, France: OECD, 1985).
  303. Organisation for Economic Co-operation and Development, Industry Committee, "Current Major Themes in Industrial Policy Tax Reform and Industrial Performance," unpublished document, OECD, Paris, France, September 1988.
  304. Organisation for Economic Co-operation and Development, *OECD Health Data-Comparative Analysis of Health Systems* (Paris, France: CREDES-OECD, 1991).
  305. Palca, J., "Changes Ahead for Gene Therapy Review Process? and Four Thumbs Up, One Thumb Down," *Science* 253:624-625, 1991.
  306. Panem, S., *The Interferon Crusade* (Washington, DC: The Brookings Institution, 1984).
  307. Parker, J., "Regulatory Stringency and the International Diffusion of Drugs," *Arne Ryde Symposium on Pharmaceutical Economics*, B. Lindgren (ed.) (Stockholm, Sweden: Swedish Institute for Health Economics and Liber Forlag, 1984).
  308. Parry, T. G., and Thwaites, R.M.A., *The Pharmaceutical Industry in Australia Benchmark*

- Study* (North Sydney, Australia: Australian Pharmaceutical Manufacturers Association, 1988).
309. Patented Medicine Prices Review Board of Canada, *First Annual Report 1988*, Catalog Number **RG79-1/1989** (Ottawa, Canada: Ministry of Supply and Services Canada, 1989).
310. Patented Medicine Prices Review Board of Canada, *Second Annual Report 1989*, Catalog Number **RG79-1/1990** (Ottawa, Canada: Ministry of Supply and Services Canada, 1990).
311. Patented Medicine Prices Review Board of Canada, *Fourth Annual Report 1991*, Catalog Number **RG79-1/1991** (Ottawa, Canada: Ministry of Supply and Services Canada, 1992).
312. Patterson, A., Chief of Drugs and Pharmacies, U.S. Department of Veterans Affairs, Washington, DC, personal communication, February 27, 1992.
313. Pearson, P.L., Lucier, R., and Brunn, C., "Databases to Serve the Genome Program and the Medical Genetics Community," *Etiology of Human Disease at the DNA Level*, J. Lindsten and U. Petterson (eds.) (New York: Raven Press, 1991).
314. Peck, C., "Testimony Before the U.S. Department of Health and Human Services Advisory Committee on the FDA, Subcommittee on Human Drugs and Biologic," Washington, DC, September 27, 1990.
315. Peltzman, S., *Regulation of Pharmaceutical Innovation: The 1962 Amendments*, AEI Evaluative Series (Washington, DC: American Enterprise Institute, 1974).
316. Perkin-Elmer Cetus, *PCR Bibliography Volume 1, No. 5* (Norwalk, CT: Perkin Elmer Cetus, 1990),
317. Persinger, G., Deputy Vice President of Health Care Systems, Pharmaceutical Manufacturers Association, Washington, DC, personal communications, January 28, 1991, March 31, 1992, and December 2, 1992.
318. Peterson, M. A., *Civil Justice in the 1980s: Trends in Jury Trials and Verdicts in California and Cook County* (Santa Monica, CA: The Rand Corporation, 1987).
319. Pharma Japan, "Chuikyo Scraps Bulk Line Method in Favor of Adding 15% of NHI Price to Weighted Average Value," *Pharma Japan* 1257:1-3, 1991.
320. Pharmaceutical Manufacturers Association, *Annual Survey Reports, 1970-1991* (Washington, DC: Pharmaceutical Manufacturers Association, 1970-1991).
321. Pharmaceutical Manufacturers Association, *1981-1983 Statistical Report*, (Washington, DC: Pharmaceutical Manufacturers Association, 1983).
322. Pharmaceutical Manufacturers Association, 'Patents on Medicinal Products, unpublished report, Washington, DC, 1988.
323. Pharmaceutical Manufacturers Association, *Biotechnology Medicines in Development*, (Washington, DC: Pharmaceutical Manufacturers Association, 1991).
324. Pharmaceutical Manufacturers Association, *1989-1991 Statistical Report: The U.S. Pharmaceutical Industry*, (Washington, DC: Pharmaceutical Manufacturers Association, 1991).
325. Pharmaceutical Manufacturers Association, advertisement in the *Washington Post*, January 30, 1992, p. A21.
326. Pharmaceutical Manufacturers Association, *Annual Survey Report 1992* (Washington, DC: Pharmaceutical Manufacturers Association, 1992).
327. Pharmaceutical Manufacturers Association, *Directory of Prescription Drug Indigent Programs* (Washington, DC: Pharmaceutical Manufacturers Association, 1992).
328. *Pharmaprojects* (Surrey, United Kingdom: P.J.B. Publications Ltd., 1991).
329. Phillips, L. M., Nudelman, E., Gaeta, F. C. A., et al., "ELAM-1 Mediates Cell Adhesion by Recognition of a Carbohydrate Ligand, Sial-Le<sup>1</sup>," *Science* 250:1130-1132, 1991.
330. Pindyck, R. S., "Irreversibility, Uncertainty, and Investment," *Journal of Economic Literature* 29:1110-1148, September 1991.
331. Porter, R.J., "Conflict of Interest in Research: Personal Gain-The Seeds of Conflict," *Biomedical Research: Collaboration and Conflict of Interest*, R.J Porter and T.E. Malone (eds.) (Baltimore, MD: The Johns Hopkins University Press, 1992).
332. Pradhan, S. B., *International Pharmaceutical Marketing* (Westport, CT: Quorum Books, 1983).
333. Prescott, L. F., "The Need for Improved Drug Delivery in Clinical Practice," *Novel Drug Delivery and Its Applications*, L.F. Prescott and W.S. Nimmo (eds.) (New York: Wiley, 1989).

334. Price Waterhouse, *Doing Business in the United States: Information Guide and Supplement* (New York, NY: Price Waterhouse, 1987).
335. Price Waterhouse, *Doing Business in the United States: Information Guide and Supplement* (New York, NY: Price Waterhouse, 1989).
336. **Provine, W. B.**, *The Origins of Theoretical Population Genetics* (Chicago, IL: University of Chicago Press, 1971).
337. Public Citizen Health Research Group, "Comments to the Office of Federal Patent Licensing, National Technical Information Service," unpublished memorandum, Washington, DC, April 29, 1988.
338. **Quirnbach, H. C.**, "R&D: Competition Risk and Performance," MRG Working Paper No. M8742, University of Southern California, Los Angeles, CA, September 13, 1989.
339. Ragusa, C., Manager of Analytic Services, **IMS International, Inc.**, Plymouth Meeting, PA, personal communication, May 13, 1992.
340. Randall, B., and McLaughlin, M., *Drug Approval: Access to Experimental Drugs for Severely Ill Patients*, Congressional Research Service Issue Brief No. **IB90016**, archived (Washington, DC: U.S. Government Printing Office, January 24, 1991).
341. Rathmann, G., Chairman and Chief Executive Officer, **ICOS Corp.**, Bothell, WA, personal communication, February 5, 1991.
342. Redwood, H., *The Pharmaceutical Industry: Trends, Problems, and Achievements* (Suffolk, United Kingdom: **Oldwicks Press**, 1988).
343. Regan, K., Director of Division on Planning and Evaluation, Office of Deputy Associate Administrator for Policy Coordination, Alcohol, Drug Abuse, and Mental Health Administration, National Institutes of Health, Public Health Service, U.S. Department of Health and Human Services, **Rockville, MD**, personal communication, February 4, 1991.
344. Reich, M. R., "Why the Japanese Don't Export More Pharmaceuticals: Health Policy as Industrial Policy," *California Management Review* 32(2):124-150, 1990.
345. Reich, M. R., "Policy Challenges Facing the Pharmaceutical Industry in Japan," paper presented at the 1991 Pharmaceutical Manufacturers Association International Section Annual Meeting, Scottsdale, AZ, April 23-26, 1991.
346. **Reinganum, J. F.**, "A Dynamic Game of R and D: Patent Protection and Competitive Behavior," *Econometric* 50:671-688, May 1982.
347. **Relman, A. S.**, "Economic Incentives in Clinical Investigation," *New England Journal of Medicine* 320:933-934, 1989.
348. **Reuter, P.**, "The Economic Consequences of Expanded Corporate Liability: An Exploratory Study," The Rand Corporation, The Institute for Civil Justice, Santa Monica, CA. N-2807 - **ICJ**, November 1988.
349. *Reyes v. Wyeth Labs*, 498 F. 2d 1264 (5th Cir. 1974).
350. Richard, B. W., Melville, A., and Lasagna, L., "Postapproval Research as a Condition of Approval: An Update, 1985 -1986," *Journal of Clinical Research and Drug Development* 3:247-257, 1989.
351. **Riordan, J. R.**, **Rommens, J. M.**, **Kerem, B. S.**, et al., "Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA," *Science* 245:1066-1072, 1989.
352. Roberts, K., and **Weitzman, M. L.**, "Funding Criteria for Research, Development, and Exploration Projects," *Econometrica* 49(5):1261-1288, 1981.
- 352a. Roll, R., "A Critique of the Asset Pricing Theory's Tests," *Journal of Financial Economics* p. 129-176, March 1977.
353. **Rommens, J.M.**, **Iannuzzi, M. C.**, **Kerem, B.-S.**, et al., "Identification of the Cystic Fibrosis Gene: Chromosome Walking and Jumping," *Science* 245:1059-1065, 1989.
354. **Rosenberg, S. A.**, **Blaese, R. M.**, and **Anderson, W.F.**, "The N2-TIL Human Gene Transfer Clinical Protocol," *Human Gene Therapy* 1:73-92, 1990.
355. **Rossiter, B. J. F.**, and **Caskey, C. T.**, *Report of the MDA Gene Therapy Conference (Tucson, AZ: Muscular Dystrophy Association, 1991)*.
356. **Rovner, J.**, "Prescription Drug Prices," *The CQ Researcher* 2(26):599-604, 1992.
357. **Ruscio, K.**, "Tax Incentives and Innovation," unpublished manuscript, 1981.
358. **Saiki, R. K.**, **Gelfand, D. H.**, **Stoffel, S.**, et al., "Primer-Directed Enzymatic Amplification of DNA With a Thermostable DNA Polymerase," *Science* 239:487-491, 1988.

359. **Salamon, G.**, "Cash Recovery Rates and Measures of Firm Profitability," *The Accounting Review* 57(2):292-302, 1982.
360. **Salamon, G.**, "Accounting Rates of Return," *American Economic Review* 75(3):495-504, 1985.
361. **Scheiber, G. J., Poullier, J.-P., and Greenwald, L.M.**, "Health Care Systems in Twenty-Four Countries," *Health Affairs* 10(3):22-38, Fall 1991.
362. **Scheren, J.**, Vice President of Education Research Information, National Wholesale Drug-gists Association, Alexandria, VA, personal communication, May 7, 1992.
363. **Scherer, F.M.**, "Research and Development: Resource Allocation Under Rivalry," *Quarterly Journal of Economics* 81 :359-394, August 1967.
364. **Scherer, F. M.**, "Inflation, Capital Budgeting and the Long View," School of Government, Harvard University, unpublished survey, Cambridge, MA, 1983.
365. **Scherer, F.M.**, *Innovation and Growth: Schumpeterian Perspectives* (Cambridge, MA: The MIT Press, 1984).
366. **Scherer, F. M., and Ross, D.**, *Industrial Market Structure and Economic Performance, 3rd Edition* (Boston, MA: Houghton Mifflin Company, 1990).
367. **Schnee, J. E.**, "Development Cost: Determinants and Overruns," *Journal of Business* 45(3):347-374, 1972.
368. **Schondelmeyer, S.W.**, "Economic Impact of Multiple Source Competition on Originator Products," contract paper prepared for Office of Technology Assessment, U.S. Congress, December 1991.
369. **Schondelmeyer, S.W.**, "Economic Impact of Multiple Source Competition on Originator Products," contract paper prepared for Office of Technology Assessment, U.S. Congress, addendum, February 1992.
370. **Schondelmeyer, S. W.**, Professor, University of Minnesota, Minneapolis, MN, personal communications, February 6, 1992 and March 15, 1992.
371. **Schwartz, T. M.**, "Products Liability Law and Pharmaceuticals: Developments and Divergent Trends," *Food Drug and Cosmetic Law Journal* 43:33, 1988.
372. **Schwartzman, D.**, *The Expected Return From Pharmaceutical Research* (Washington, DC: American Enterprise Institute, 1975).
373. **Scolnick, E.M.**, "Basic Research and Its Impact on Industrial R&D," *Research Technology Management* 33:22-26, November/December 1990.
374. **Scott, H. D., Thatcher-Renshaw, A., Rosenbaum, S. E., et al.**, "Physician Reporting of Adverse Drug Reactions," *Journal of the American Medical Association* 263:1785-1788, 1990.
375. *Scrip World Pharmaceutical News*, "US AIDS Research Grants Controversy," *Scrip World Pharmaceutical News* 1456:15, 1989.
376. *Scrip World Pharmaceutical News*, "Enormous Growth in U.S. CANDAS," *Scrip World Pharmaceutical News* 1536: 19-20, 1990.
- 376a. *Scrip World Pharmaceutical News*, "French Stress Efficacy/Cost Ratio," *Scrip World Pharmaceutical News* 1561:2-3, 1990.
377. *Scrip World Pharmaceutical News*, "UK PPRS as a Model in Europe," *Scrip World Pharmaceutical News* 1603:4-5, 1991.
378. *Scrip World Pharmaceutical News*, "Merck Drops Leukotriene Antagonist" *Scrip World Pharmaceutical News* 1612:22, 1991.
379. *Scrip World Pharmaceutical News*, "Leukotriene Research Making Progress," *Scrip World Pharmaceutical News* 1613:26-27, 1991.
- 379a. *Scrip World Pharmaceutical News*, "Prior Authorization as Bargaining Chip," *Scrip World Pharmaceutical News* 1617:18, 1991.
380. *Scrip World Pharmaceutical News*, "FDA Reforms Include Recognition of Non-U.S. Approvals," *Scrip World Pharmaceutical News* 1670:19, November 17, 1991.
381. *Scrip World Pharmaceutical News*, "French Reimbursement to November," *Scrip World Pharmaceutical News* 1692:4, February 14, 1992.
- 381a. *Scrip World Pharmaceutical News*, "Medicaid 'Best Price' Repeal Urged," *SCRIP World Pharmaceutical News* 1697:16, March 4, 1992.
382. *Scrip World Pharmaceutical News*, "ICI Invests More in Puerto Rico," *Scrip World Pharmaceutical News* 1700:9, March 3, 1992.
383. *Scrip World Pharmaceutical News*, "Lilly Constructing \$65 Million Facility in Puerto

- Rico," *Scrip World Pharmaceutical News* 1700:9, March 3, 1992.
384. *Scrip World Pharmaceutical News*, "Antibacterial Competition Intensifies in U.S.," *Scrip World Pharmaceutical News* 1709:26, April, 15, 1992.
385. *Scrip World Pharmaceutical News*, "Top 25 Products in 1991," *Scrip World Pharmaceutical News* 1717:28, May 13, 1992.
386. Serneus, G., and Adriaenssens, G., *Drug Prices and Drug Legislation in Europe-An Analysis of the Situation in the Twelve Member States of the European Communities*, report prepared for the Directorate-General for the Environment, Consumer Protection and Nuclear Safety of Belgium, Number 112/89 (Brussels, Belgium: Belgian Consumers' Association, 1989).
387. Shanahan, B., Manager of University Programs, Standard & Poor's Compustat Services, Inc., personal communication, January 31, 1991.
388. Shanley, M. G., and Peterson, M. A., *Comparative Justice: Civil Jury Verdicts in San Francisco and Cook Counties, 1959-1980* (Santa Monica, CA: The Rand Corporation, 1983).
389. Shulman, S., Bienz-Tadmor, B., Son See, P., et al., "Implementation of the Orphan Drug Act: 1983-1991," *Food and Law Journal* 47(4):363-404, 1992.
390. Shyam-Sunder, L., "Estimates of Cost of Capital and Risk for Firms in the U.S. Pharmaceutical Industry," paper prepared for Pfizer Inc., New York, NY, December 1991.
391. Sick, G., "Pharmaceutical Industry R&D and the Cost of Capital," paper prepared for the Office of Technology Assessment, U.S. Congress, Washington, DC, February 1992.
392. Sick, G., "Tax-Adjusted Discount Rates," *Management Science* 36(12):1432-1450, 1990.
393. *SmithKline Corporation v. Staats*, 668 F.2d 201 (3rd Cir. 1981).
394. SmithKline & French International, *The Discovery of Histamine H<sub>2</sub> -Receptors and Their Antagonists* (Philadelphia, PA: Smith Kline & French, 1982).
395. Smith, E. S., "Third Party Payment for Unapproved Uses of Approved Drugs and for Medical Care Associated With Drug Clinical Trials," report prepared for the Office of Technology Assessment, U.S. Congress, Washington, DC, January 1991.
396. Sneader, W., *Drug Discovery: The Evolution of Modern Medicines* (New York, NY: Wiley, 1985).
397. Snedden, T., Director of PACE Program, Pennsylvania Department of Aging, Harrisburg, PA, personal communication, October 31, 1991.
398. Solomon, E., "Alternative Rate of Return Concepts and Their Implications for Utility Regulation," *Bell Journal of Economics* 1:65-81, Spring 1970.
399. Spilker, B., *Multinational Drug Companies: Issues in Drug Discovery and Development* (New York, NY: Raven Press, 1989).
400. Stanley, G. R., "Use of Foreign Data in a New Drug Application," *Food Drug Cosmetic Law Journal* 36:340-344, 1981.
401. Statman, M., *Competition in the Pharmaceutical Industry: The Declining Profitability of Drug Innovation* (Washington, DC: American Enterprise Institute, 1983).
402. Stauffer, T. R., "The Measurement of Corporate Rates of Return: A Generalized Formulation," *Bell Journal of Economics* 2: 434-469, Autumn 1971.
403. Stechschulte, D. J., "Leukotrienes in Asthma and Allergic Rhinitis" [editorial], *New England Journal of Medicine* 323(25):1769-1770, 1990.
404. Stein, R. E., Partner, Blicker, Futterman and Stein, Washington, DC, personal communication, August 7, 1992.
405. Stephens, J. C., Cavanaugh, M.L., Gradie, M. I., et al., "Mapping the Human Genome: Current Status," *Science* 250:237-244 [and wall chart], October 12, 1990.
406. Stem, L., and Simon, P., "French Drug Policy," *International Journal of Technology Assessment in Health Care* 2(4):637-642, 1986.
407. Stetler, C. J., "The Pharmaceutical Industry in Review: How We Got to Where We Are," *Medical Marketing and Media* 26:40-50, October 1991.
408. Stevens, A., Secretary to the Pharmaceutical Benefits Pricing Authority of Australia, Sydney, Australia, personal communication, December 11, 1991.

409. **Stewart, G. B., III**, *The Quest for Value: A Guide for Senior Managers* (New York, NY: Harper Business, 1991).
410. Stokes, D.E., "Perceptions of the Nature of Basic and Applied Science in the United States," *Science Policy Perspectives: USA-Japan*, A. Gerstenfeld (ed.) (New York, NY: Academic Press, 1982).
411. **Stolar, M. H.**, "National Survey of Hospital Pharmaceutical Services—1982," *American Journal of Hospital Pharmacists* 40:963-969, 1983.
412. **Stolar, M.H.**, "ASHP National Survey of Hospital Pharmaceutical Services-1987," *American Journal of Hospital Pharmacy* 45:801-818, 1988.
413. **Stoll, R.R.**, "A Question of Competence: The Judicial Role in the Regulation of Pharmaceuticals," *Food Drug and Cosmetic Law Journal* 45:279-299, 1990.
414. **Sturtevant, A.H.**, *A History of Genetics* (New York, NY: Harper and Row, 1965).
415. **Swarm, J. P.**, *Academic Scientists and the Pharmaceutical Industry: Cooperative Research in Twentieth Century America* (Baltimore, MD: The Johns Hopkins University Press, 1988)
416. **Swazey, J. P.**, "Containing Risks of 'Unavoidably Unsafe' Products: Prescription Drugs and Product Liability," *The Liability Maze: The Impact of Liability Law on Safety and Innovation*, R.E. Litan and Peter W. Huber (eds.) (Washington, DC: The Brookings Institution, 1991).
417. **Tachi, R.**, chairman, **Chuikyo** (Central Social Insurance Medical Council of Japan), "The Self-Initiated Recommendations," unpublished typewritten summary of **Chuikyo** Special Committee on **NHI** Drug Prices meeting, Tokyo, Japan, May 31, 1991.
418. **Tandon, P.**, "Rivalry and the Excessive Allocation of Resources to Research," *Bell Journal of Economics* 43:301-315, 1976.
419. **Teitelman, R.**, *Gene Dreams: Wall Street, Academia, and the Rise of Biotechnology* (New York, NY: Basic Books, Inc., 1989).
420. **Temin, P.**, "Technology, Regulation, and Market Structure in the Modern Pharmaceutical Industry," *Bell Journal of Economics* 10:429-446, Autumn 1979.
421. **Thomas, L. G.**, "Regulation and Firm Size: FDA Impacts on Innovation," Columbia University Graduate School of Business, First Boston Working Paper Series, **FB-87-24**, September 1987.
422. **Thomas, L.G.**, "Regulation and Firm Size: FDA Impacts on Innovation," *Rand Journal of Economics* 21:4, Winter 1990.
423. **Tiefer, C.**, Deputy Counsel to the Clerk, Office of the General Counsel, House of Representatives, U.S. Congress, personal communication, September 4, 1991.
424. **Traina, V.M.**, "The Role of Toxicology in Drug Research and Development," *Medical Research Reviews* 3(1):43-72, 1983.
425. **Tsui, L.-C., Buchwald, M., Barker, D., et al.**, "Cystic Fibrosis Locus Defined by a Genetically Linked Polymorphic DNA Marker," *Science* 230:1054-1057, 1985.
426. **Tucker, S. A., Blozan, C., and Coppinger, P.**, "The Outcome of Research on New Molecular Entities Commencing Clinical Research in Years 1976-78," **OPE-Study 77**, unpublished manuscript, U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, **Rockville, MD**, May 1988.
427. **Tufts University, Center for Study of Drug Development**, unpublished data provided to the Office of Technology Assessment, U.S. Congress, Washington, DC, 1990.
428. **Tyle, P., and Ram, B.P.**, "Monoclonal Antibodies, Immunoconjugates, and Liposomes as Targeted Therapeutic Systems," *Targeted Therapeutic Systems*, P. Tyle and B.P. Ram (eds.) (New York, NY: Marcel Dekker, 1990),
429. *United States v. Abbott*, 597 F.2d 672 (7th Cir. 1979).
430. U.S. Congress, Congressional Budget Office, *Potential Economic Impacts of Changes in Puerto Rico's Status Under S. 712* (Washington, DC: U.S. Government Printing Office, April 1990).
431. U.S. Congress, Congressional Budget Office, "Question and Answers: Medicaid Prescription Drug Rebates," unpublished report, Congressional Budget Office, June 1992.
432. U.S. Congress, General Accounting Office, *Product Liability: Extent of Litigation Explosion in Federal Courts Questioned*, **GAO/HRD-88-36BR** (Washington, DC: U.S. Government Printing Office, January 1988).

433. U.S. Congress, General Accounting Office, *Biotechnology: Backlog of Patent Applications*, GAO/RCED-89-120-BR (Washington, DC: U.S. Government Printing Office, April 1989).
434. U.S. Congress, General Accounting Office, *Prescription Drugs: Information on Selected Drug Utilization Review Systems*, PEMD-89-18 (Washington, DC: U.S. Government Printing Office, May 1989).
435. U.S. Congress, General Accounting Office, *ADP Planning FDA's Plans to Improve Processing of Medical Device and Drug Applications*, GAO/IMTEC-89-58 (Washington, DC: U.S. Government Printing Office, June 1989).
436. U.S. Congress, General Accounting Office, *FDA Resources: Comprehensive Assessment of Staffing, Facilities, and Equipment Needed*, GAO/HRD-89-142 (Washington, DC: U.S. Government Printing Office, September 1989).
437. U.S. Congress, General Accounting Office, *Tax Policy and Administration: The Research Tax Credit Has Stimulated Some Additional Research Spending*, GAO/GGD-89-114 (Washington, DC: U.S. Government Printing Office, September 1989).
438. U.S. Congress, General Accounting Office, *Tax Policy: 1987 Company Effective Tax Rates Higher Than in Prior Years*, GAO/GGD-90-69 (Washington, DC: Government Printing Office, May 1990).
439. U.S. Congress, General Accounting Office, *FDA Premarket Approval: Process of Approving Ansaid as a Drug*, GAO/HRD-92-85 (Washington, DC: U.S. Government Printing Office, April 1992).
- 439a. U.S. Congress, General Accounting Office, *Prescription Drugs: Companies Typically Charge More in the United States Than in Canada*, GAO/HRD-92-110 (Washington, DC: U.S. Government Printing Office, September 1992).
440. U.S. Congress, House of Representatives, Committee on Energy and Commerce, unpublished data, Washington, DC, 1983.
441. U.S. Congress, Joint Committee on Taxation, *General Explanation of the Tax Reform Act of 1986* (Washington, DC: U.S. Government Printing Office, 1986).
442. U.S. Congress, Library of Congress, Congressional Research Service, "The Product Liability Reform Act: S. 1400, 101st Congress, prepared by Henry Cohen, Washington, DC, August 1989.
443. U.S. Congress, Office of Technology Assessment, *A Review of Selected Federal Vaccine and Immunization Policies Based on Case Studies of Pneumococcal Vaccine*, OTA-H-96 (Washington, DC: U.S. Government Printing Office, September 1979).
444. U.S. Congress, Office of Technology Assessment, *Compensation for Vaccine-Related Injuries*, OTA-TM-H-6 (Washington, DC: U.S. Government Printing Office, November 1980).
445. U.S. Congress, Office of Technology Assessment, *Commercial Biotechnology: An International Analysis*, OTA-BA-218 (Washington, DC: U.S. Government Printing Office, January 1984).
446. U.S. Congress, Office of Technology Assessment, *Medicare's Prospective Payment System: Strategies for Evaluating Cost Quality and Medical Technology*, OTA-H-262 (Washington, DC: U.S. Government Printing Office, October 1985).
447. U.S. Congress, Office of Technology Assessment, *Alternatives to Animal Use in Research, Testing, and Education*, OTA-BA-273 (Washington, DC: U.S. Government Printing Office, February 1986).
448. U.S. Congress, Office of Technology Assessment, *Losing a Million Minds: Confronting the Tragedy of Alzheimer's Disease and Other Dementias*, OTA-BA-323 (Washington, DC: U.S. Government Printing Office, April 1987).
449. U.S. Congress, Office of Technology Assessment, *Healthy Children: Investing in the Future*, OTA-H-345 (Washington, DC: U.S. Government Printing Office, February 1988).
450. U.S. Congress, Office of Technology Assessment, *New Developments in Biotechnology, U.S. Investment in Biotechnology*, OTA-BA-360 (Washington, DC: U.S. Government Printing Office, July 1988).
451. U.S. Congress, Office of Technology Assessment, *Recombinant Erythropoietin: Payment Options for Medicare*, OTA-H-451 (Washington, DC: U.S. Government Printing Office, May 1990).

452. U.S. Congress, Office of **Technology** Assessment, *Federally Funded Research: Decisions for a Decade, OTA-SET-490* (Washington, DC: U.S. Government Printing Office, May 1991),
453. U.S. Congress, Office of Technology Assessment, *Biotechnology in a Global Economy, OTA-BA-494* (Washington, DC: U.S. Government Printing Office, October 1991).
454. U.S. Congress, Office of Technology Assessment, *Home Drug Infusion Therapy Under Medicare, OTA-H-510* (Washington, DC: U.S. Government Printing Office, May 1992).
455. U.S. Congress, **Office** of Technology Assessment, *Federal and Private Roles in the Development and Provision of Alglucerase Therapy for Gaucher Disease, OTA-BP-H-104* (Washington, DC: U.S. Government Printing Office, October 1992).
456. U.S. Congress, Senate, Report 99-283 in **Legislative History to Public Law 99-502, 1986 U.S. CCAN 3442-63.**
457. U.S. Congress, Senate, Special Committee on Aging, "The Drug Manufacturing Industry: A Prescription for **Profits**," **Comm. Pub. No. 102-50** (Washington, DC: U.S. Government Printing Office, September 1991).
458. U.S. Congress, Senate, Special Committee on Aging, "A Status Report: Accessibility and Affordability of Prescription Drugs for Older Americans (Annotated)," Serial No. 102-Q (Washington, DC: U.S. Government Printing Office, September 1992).
459. U.S. Department of Agriculture, Animal and Plant Health Inspection, *Animal Welfare Enforcement, FY 74*, report to the President of the Senate and Speaker of the House of Representatives, 1975.
460. U.S. Department of Agriculture, Animal and Plant Health Inspection, *Animal Welfare Enforcement, FY 87*, report to the President of the Senate and Speaker of the House of Representatives, 1988.
461. U.S. Department of Commerce, International Trade Administration, *U.S. Industrial Outlook '92* (Washington, DC: U.S. Government Printing Office, January 1992).
462. U.S. Department of Health and Human Services, Advisory **Com mitee** on the Food and Drug Administration, *Final Report of the Advisory Committee on the Food and Drug Administration* (Washington, DC: U.S. Government Printing Office, 1991).
463. U.S. Department of Health and Human Services, Health Care Financing Administration, *Health Care Financing Program Statistics: Medicare and Medicaid Data Book, 1990*, HCFA Publication No. 03314 (Washington, DC: U.S. Government Printing Office, 1991).
464. U.S. Department of Health and Human Services, Health Care Financing Administration, **Office** of National Health Statistics, Office of the Actuary, unpublished data, Baltimore, MD, March 1992.
465. U.S. Department of Health and Human Services, Health Resources Services Administration, Vaccine Injury Compensation Program, unpublished data **from Weekly Status Report, Rockville, MD**, June 18, 1991.
466. U.S. Department of Health and Human Services, Office of Inspector General, *Promotion of Prescription Drugs Through Payments and Gifts, DHHS Pub. No. (OEI) 01-90-00480* (Washington, DC: U.S. Government Printing Office, 1990).
467. U.S. Department of Health **and** Human Services, President's Cancer Panel, *Final Report of the National Committee to Review Current Procedures for Approval of New Drugs for Cancer and AIDS*, unpublished document, U.S. Department of Health and Human Services, Washington, DC, August 1990.
468. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research, *Office of Drug Evaluation Statistical Report: 1983*, unpublished document, U.S. Department of Health and Human Service, **Rockville, MD**, 1984.
469. U.S. Department of Health and Humans Services, Public Health Service, Food and Drug **Administration**, *Formatting, Assembling and Submitting New Drug and Antibiotic Applications (Rockville, MD: U.S. Department of Health and Human Services, February 1987).*
470. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, "Orphan Designations Pursuant to Section 526 of the Federal Food, Drug and Cosmetic Act as Amended by the **Orphan**

- Drug Act (Public Law 97-414) Through December 31, 1989," unpublished document, U.S. Department of Health and Human Services, Rockville, MD, 1989.
471. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, *From Test Tube to Patient: New Drug Development in the U. S., An FDA Consumer Special Report*, DHHS Pub. No. (FDA) 90-3168 (Washington, DC: U.S. Government Printing Office, 1990).
472. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research, *Office of Drug Evaluation Statistical Report: 1986*, U.S. Department of Health and Human Service, Rockville, MD, 1987.
473. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research, *Approved Drug Products, 10th edition* (Washington, DC: U.S. Government Printing Office, 1990).
474. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research, *Office of Drug Evaluation Statistical Report: 1990*, U.S. Department of Health and Human Service, Rockville, MD, 1991.
475. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research, *Office of Drug Evaluation Statistical Report: 1991*, U.S. Department of Health and Human Service, Rockville, MD, 1992.
476. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, "Research Patient Care Costs Supported by NIH Sponsored Agreements," *NIH Extramural Research Manual* (Washington, DC: U.S. Government Printing Office, March 1986).
477. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, *1987 NIH Almanac* (Washington, DC: U.S. Government Printing Office, 1987).
478. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, "Outside Work and Activities," revision to *NIH Manual*, chapter 2300-735-4, mimeograph, September 1, 1988.
479. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Alcohol, Drug Abuse and Mental Health Administration, Office of Technology Transfer, Patent Policy Board, *Materials Transfer Agreement* (Bethesda, MD: National Institutes of Health, May 22, 1989).
480. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, *Academic Research Equipment and Equipment Needs in the Biological Sciences: 1984-1987* (Bethesda, MD: National Institutes of Health, June 1989).
481. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, *Extramural Trends: FY 1979-1988* (Bethesda, MD: National Institutes of Health, June 1989).
482. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, *NIH Data Book 1989*, NIH Pub. No. 90-1261 (Bethesda, MD: National Institutes of Health, December 1989).
483. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, *Data Book 1990* (Washington, DC: U.S. Government Printing Office, 1990).
484. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Alcohol, Drug Abuse and Mental Health Administration, *NIH/ADAMHA Technology Transfer: The Federal Technology Transfer Act and Collaboration With Industry*, NIH/ADAMHA training manual, sponsored by the NIH/ADAMHA Patent Policy Board and Office of Invention Development, November 1989.
485. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Alcohol, Drug Abuse and Mental Health Administration, Division of Program Analysis, Office of Extramural Program, *ADAMHA Data Source Book FY 1989*, Report No. 90-21 (Rockville, MD: Office of Extramural Programs, ADAMHA, 1990).
486. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, Alcohol, Drug Abuse and Mental

- Health Administration, Office of **Technology Transfer**, Patent Policy Board, "Policy Statement on Cooperative Research and Development Agreements and Intellectual Property Licensing, March 27, 1989," *PHS Technology Transfer Directory (NIH/ADAMHA/CDC)* (Washington, DC: U.S. Government Printing Office, 1990).
- 486a. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of General Medical Sciences, *Pharmacological Sciences Program's Biennial Report for Fiscal Years 1988-1989* (Bethesda, MD: National Institutes of Health, September 1990).
487. U.S. Department of Health and Human Services, Public Health Service, Office of the Assistant Secretary for Planning and Evaluation, "Medicare Coverage for Investigational Drugs: Exploring the Options," unpublished document, U.S. Department of Health and Human Services, Washington, DC, 1990.
488. U.S. Department of Health and Human Services and U.S. Department of Energy, *Understanding Our Genetic Inheritance: The First Five Years, FY 1991-1995, DOE/ER-0452P* (Springfield, VA: National Technical Information Service, 1990).
489. U.S. Department of Justice, *Report of the Tort Policy Working Group on the Causes, Extent and Policy Implications of the Current Crisis in Insurance Availability and Affordability* (Washington, DC: U.S. Government Printing Office, 1986).
490. U.S. Department of Justice, Tort Policy Working Group, *An Update on the Liability Crisis* (Washington, DC: U.S. Government Printing Office, 1987).
491. U.S. Department of Labor, Bureau of Labor Statistics, Bulletin 2363, *Employee Benefits in Medium and Large Firms, 1989* (Washington, DC: U.S. Government Printing Office, June 1990).
492. U.S. Department of Treasury, Internal Revenue Service, Statistics of Income Division, *Source Book, Statistics of Income, 1987, Corporate Income Tax Returns, IRS Publication 1053* (Washington, DC: U.S. Government Printing Office, 1987).
493. U.S. District Court, *People With AIDS Health Group, William Ceyrolles, and William Neithamer v. Burroughs Wellcome Company and the United States of America*, Civil Action No. 91-574, March 19, 1991.
494. U.S. District Court for the District of Columbia, "Memorandum in Support of Plaintiff's Motions for a Temporary Restraining Order and for a Preliminary Injunction," Civil Action 87-0605, 1987.
495. U.S. District Court for the District of Columbia, "Memorandum of Points and Authorities for Intervenor-Defendant Eli Lilly and Company in Opposition to Plaintiff's Motion for a Preliminary Injunction," Civil Action No. 87-0605, 1987.
496. Uzzell, J.K., and Meyer, G. F., "Learning Lessons at the School of NDA Submissions," *Pharmaceutical Executive* 10(6):82-86, 1990.
497. Van Horn, C. E., Special Assistant to the Assistant Commissioner for Patents, U.S. Patent and Trademark Office, U.S. Department of Commerce, personal communications, April 5, 1990, March 7, 1991, and September 8, 1992.
498. Venuti, M. C., "Molecular Genetics and Drug Discovery," *Molecular Genetic Medicine, Volume 1, T. Friedmann (ed.)* (San Diego, CA: Academic Press, 1991).
499. Villeneuve, J. E., Director, Drug Regulatory Affairs, Roche Pharmaceuticals, Nutley, NJ, personal communication, September 8, 1992.
500. Virts, J. R., and Weston, J.F., "Returns to Research and Development in the U.S. Pharmaceutical Industry," *Managerial and Decision Economics* 1(3):103-111, 1980.
501. Viscusi, Kip W., and Moore, Michael, J., "An Industrial Profile of the Links Between Product Liability and Innovation," *The Liability Maze: The Impact of Liability Law on Safety and Innovation*, Robert E. Litan and Peter W. Gruber (eds.) (Washington, DC: The Brookings Institution, 1991).
502. Wade, V. A., Mansfield, P. R., and McDonald, P. J., "Drug Companies' Evidence to Justify Advertising," *The Lancet* 1989, pp. 1261-1263.
503. Wagner, J. L., Senior Associate, Office of Technology Assessment, U.S. Congress, Washington, DC, "Statement," *Strategies for Containing Medicaid Prescription Drug Costs*, hearing

- before the Senate Committee on Finance, U.S. Congress, Washington, DC, September 17-19, 1990.
504. Wainwright, B. J., Scambler, P. J., Schmidtke, J., et al., "Localization of Cystic Fibrosis Locus to Human Chromosome 7cen-q22," *Nature* 322:467-470, 1985.
505. *Wall Street Journal*, "Drug Costs Outstrip U.S. Consumer Prices New Report Discloses," *Wall Street Journal* September 11, 1992, p. B13.
506. Walz, G., Aruffo, A., Kolanus, W., et al. "Recognition by ELAM-1 of the Sial-Le<sup>1</sup> Determinant on Myeloid and Tumor Cells," *Science* 250:1132-1135, 1990.
507. Warden, W. M., "The Drug Lag Revisited: Comparisons by Therapeutic Area of Patterns of Drugs Marketed in the U.S. and Great Britain From 1972 Through 1976," *Clinical Pharmacology and Therapeutics* 24:499-524, 1978.
508. Watanabe, T., "Japanese Pharmaceutical Industry Faces Growing-and Shrinking—Pains," *Business Japan* 31:71-74, 1986.
509. Watson, J. D., and Crick, F. H. C., "Genetical Implications of the Structure of Deoxyribonucleic Acid," *Nature* 171:737-738, May 30, 1953.
510. Weber, N., *Product Liability: The Corporate Response*, Research Report 893 (New York, NY: The Conference Board, Inc., 1987).
511. Webster, A. J., and Etzkowitz, H., *Academic-Industry Relations: The Second Academic Revolution: A Framework Paper for the Proposed Workshop on Academic-Industry Relations* (London, England: Science Policy Support Group, Monograph, 1991).
512. Webster, A. J., and Constable, J., "The Role of Hybrid Coalitions in Commercializing Public Sector Science," unpublished manuscript, Anglia College, Cambridge, England, 1989.
513. Weinberg, A. M., "Criteria for Scientific Choice," *Minerva* 1:159-171, Winter 1963.
514. Weiner, J., "Campus Capitalism: Harvard Chases BioTech Bucks," *The Nation* 248:12-16, January 2, 1989.
515. Weiner, J. P., Lyles, A., Steinwachs, D. M., et al., "Impact of Managed Care on Prescription Drug Use," *Health Affairs* 10(1):140-153, Spring 1991.
516. Weisbrod, B. A., "The Health Care Quadrilemma: An Essay on Technological Change, insurance, Quality of Care, and Cost Containment," *Journal of Economic Literature* 29:523-552, June 1991.
- 516a. Weissinger, J., Center for Drug Evaluation and Research, Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services, Rockville, MD, personal communication, March 1991.
517. Wells, J., Pharmacy Program Manager, Division of Medicaid, Florida Department of Health and Rehabilitative Services, Tallahassee, FL, personal communication, 1990.
518. White, R. L., Woodward, S., Leppert, M., et al., "A Closely Linked Genetic Marker for Cystic Fibrosis," *Nature* 318:382-384, 1985.
519. Wiggins, S. N., "Product Quality Regulation and New Drug Introductions: Some New Evidence From the 1970s," *The Review of Economics and Statistics* 63(4):615-619, 1981.
520. Wiggins, S. N., *The Cost of Developing a New Drug* (Washington, DC: Pharmaceutical Manufacturers Association, 1987).
521. Wilkes, M. S., Doblin, B., Shapiro, M., "Pharmaceutical Advertisements in Leading Medical Journals: Experts' Assessments," *Annals of Internal Medicine* 116:912-919, 1992.
522. Wolfe, S. M., Director, Public Citizen Health Research Group, Washington, DC, "Statement," *Product Liability Reform Act*, hearing before the Subcommittee on the Consumer, Committee on Commerce, Science, and Transportation, Senate, U.S. Congress, May 10, 1990, Serial No. 101-743 (Washington, DC: U.S. Government Printing Office, 1990).
523. Wolski, K. P., remarks at "Drug Approvals in the United States and Abroad," seminar sponsored by the Institute for Alternative Futures Foresight, Washington, DC, October 7, 1991.
524. Woltman, R., "Reviewing the Bidding: R&D Costs and Profitability of New Chemical Entities," *Journal of Research in Pharmaceutical Economics* 1(3):49-65, 1989.
525. Wozny, J. A., "The Research Tax Credit: New Evidence on Its Effects," *Proceedings of the Eighty-Second Annual Conference of the National Tax Association-Tax Institute of America* 1989, pp. 223-228.
526. Yoshikawa, A., Associate Director, Comparative Health Care Research Project, Stanford

- University, Stanford, CA, personal communication, December 10, 1991.
527. Yoshikawa, A., **Hayase** Fellow, Asia Pacific Research Center, Stanford University, Palo Alto, CA, personal communication, March 5, 1992.
528. Young, F.E., Norris, **J.A.**, Levitt, **J.A.**, et al., "The FDA's New Procedures for the Use of Investigational Drugs in Treatment," *Journal of the American Medical Association* 259(15): 2267-2270, 1988.